Related Experiment Video
Updated: May 23, 2026
10:59
Label-Free Imaging of Lipid Storage Dynamics in Caenorhabditis elegans using Stimulated Raman Scattering Microscopy
Published on: May 28, 2021
Daf-2 signaling modifies mutant SOD1 toxicity in C. elegans
Marco Boccitto1, Todd Lamitina, Robert G Kalb
1Department of Pediatrics, Division of Neurology, Children's Hospital of Philadelphia Research Institute, Philadelphia, Pennsylvania, United States of America. boccitto@mail.med.upenn.edu
Plos One
|March 30, 2012
Summary
Reducing DAF-2 Insulin/IGF-1 signaling improves locomotion and decreases SOD1 aggregates in a model of Amyotrophic Lateral Sclerosis (ALS). This suggests potential therapeutic benefits for ALS by targeting this pathway.
Area of Science:
- Neuroscience
- Genetics
- Aging Research
Background:
- The Insulin/IGF-1 signaling (IIS) pathway, regulated by DAF-2, influences longevity and healthspan.
- Aging is a primary risk factor for neurodegenerative diseases like Amyotrophic Lateral Sclerosis (ALS).
Purpose of the Study:
- To investigate if DAF-2 signaling impacts the pathology of ALS in a *C. elegans* model.
- To explore the therapeutic potential of manipulating DAF-2 signaling for ALS treatment.
Main Methods:
- Utilized *Caenorhabditis elegans* expressing mutant G85R superoxide dismutase 1 (SOD1) to model ALS.
- Reduced DAF-2 signaling using a hypomorphic allele and neuronally targeted RNA interference.
- Assessed locomotion and quantified insoluble SOD1 aggregates.
Main Results:
- Mutant SOD1 expression impaired locomotion and increased SOD1 aggregation.
- Reduced DAF-2 signaling significantly improved locomotion and decreased SOD1 aggregates.
- These improvements were dependent on DAF-16, a downstream component of the IIS pathway.
Conclusions:
- DAF-2 Insulin/IGF-1 signaling modulates ALS pathology in a *C. elegans* model.
- Targeting the DAF-2 pathway shows promise for developing novel therapeutic strategies for ALS.
